Read More

BiomX To Host Virtual Key Opinion Leader Event To Review The Results From Part 2 Of Phase 1b/2a Trial Of BX004 In Cystic Fibrosis Patients With Chronic Pseudomonas aeruginosa Infections On December 4, 2023

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL

PHGE